JP7438123B2 - 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体 - Google Patents

腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体 Download PDF

Info

Publication number
JP7438123B2
JP7438123B2 JP2020548920A JP2020548920A JP7438123B2 JP 7438123 B2 JP7438123 B2 JP 7438123B2 JP 2020548920 A JP2020548920 A JP 2020548920A JP 2020548920 A JP2020548920 A JP 2020548920A JP 7438123 B2 JP7438123 B2 JP 7438123B2
Authority
JP
Japan
Prior art keywords
amino acids
cells
seq
domain
acids long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020548920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518108A5 (cg-RX-API-DMAC7.html
JP2021518108A (ja
Inventor
テンペラ,ジャコモ
シー. ジェンセン,マイケル
Original Assignee
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) filed Critical シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート)
Publication of JP2021518108A publication Critical patent/JP2021518108A/ja
Publication of JP2021518108A5 publication Critical patent/JP2021518108A5/ja
Priority to JP2023198981A priority Critical patent/JP7745616B2/ja
Application granted granted Critical
Publication of JP7438123B2 publication Critical patent/JP7438123B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020548920A 2018-03-14 2019-03-12 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体 Active JP7438123B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023198981A JP7745616B2 (ja) 2018-03-14 2023-11-24 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643055P 2018-03-14 2018-03-14
US62/643,055 2018-03-14
PCT/US2019/021823 WO2019178078A1 (en) 2018-03-14 2019-03-12 Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198981A Division JP7745616B2 (ja) 2018-03-14 2023-11-24 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2021518108A JP2021518108A (ja) 2021-08-02
JP2021518108A5 JP2021518108A5 (cg-RX-API-DMAC7.html) 2022-03-18
JP7438123B2 true JP7438123B2 (ja) 2024-02-26

Family

ID=67908477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548920A Active JP7438123B2 (ja) 2018-03-14 2019-03-12 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体
JP2023198981A Active JP7745616B2 (ja) 2018-03-14 2023-11-24 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023198981A Active JP7745616B2 (ja) 2018-03-14 2023-11-24 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体

Country Status (13)

Country Link
US (2) US12152079B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765041A4 (cg-RX-API-DMAC7.html)
JP (2) JP7438123B2 (cg-RX-API-DMAC7.html)
KR (1) KR102805003B1 (cg-RX-API-DMAC7.html)
CN (1) CN112236151A (cg-RX-API-DMAC7.html)
AU (1) AU2019234573B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018670A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093810A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091982A1 (cg-RX-API-DMAC7.html)
IL (2) IL277267B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020009463A (cg-RX-API-DMAC7.html)
SG (1) SG11202008795SA (cg-RX-API-DMAC7.html)
WO (1) WO2019178078A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178085A1 (en) 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
MX2022014203A (es) * 2020-05-12 2023-02-22 Lyell Immunopharma Inc Espaciadores de receptores de antígenos quiméricos (car).
CN115246883B (zh) * 2021-02-02 2025-04-11 浙江理工大学 一种抗人源IL13Ra2鲨鱼单域抗体或其抗原结合片段和应用
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JP2024514101A (ja) * 2021-04-01 2024-03-28 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Il-13ra2キメラ抗原受容体および使用方法
WO2023274380A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用
CN116589585B (zh) * 2021-12-29 2023-11-24 华道(上海)生物医药有限公司 一种抗IL13Ra2的纳米抗体及其应用
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
CN114805581B (zh) * 2022-06-29 2022-10-14 上海优替济生生物医药有限公司 靶向il13ra2的抗体、嵌合抗原受体及其用途
US20260151429A1 (en) * 2022-08-25 2026-06-04 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025154925A1 (ko) * 2024-01-18 2025-07-24 엑셀라몰(주) IL13Ra2에 결합하는 폴리펩타이드 약물 접합체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503295A (ja) 2012-11-07 2016-02-04 ファイザー・インク 抗il−13受容体アルファ2抗体および抗体−薬物コンジュゲート
JP2016525881A (ja) 2013-05-14 2016-09-01 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体(car)t細胞のヒト応用
JP2017529081A (ja) 2014-09-19 2017-10-05 シティ・オブ・ホープCity of Hope 養子t細胞療法のためのセントラルメモリーt細胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
EP2929045B1 (en) 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
EP3250609A4 (en) * 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
HK1256130A1 (zh) * 2015-07-21 2019-09-13 City Of Hope 用於嵌合抗原受体和其他受体的表达的t细胞
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
JP7189019B2 (ja) 2016-02-05 2022-12-13 シティ・オブ・ホープ 中枢神経系の癌の治療のための操作されたt細胞の投与
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
JP7295795B2 (ja) 2016-07-29 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 免疫調節ポリペプチドならびに関連する組成物および方法
US12083148B2 (en) * 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
WO2019178085A1 (en) 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503295A (ja) 2012-11-07 2016-02-04 ファイザー・インク 抗il−13受容体アルファ2抗体および抗体−薬物コンジュゲート
JP2016525881A (ja) 2013-05-14 2016-09-01 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体(car)t細胞のヒト応用
JP2017529081A (ja) 2014-09-19 2017-10-05 シティ・オブ・ホープCity of Hope 養子t細胞療法のためのセントラルメモリーt細胞
JP2017534262A (ja) 2014-09-19 2017-11-24 シティ・オブ・ホープCity of Hope L13Rα2を標的とする共刺激性キメラ抗原レセプターT細胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jonnalagadda M. et al.,Efficient selection of genetically modified human T cells using methotrexate- resistant human dihydrofolate reductase,Gene Ther,2013年,Vol. 20,pp. 853-860
Krenciute G. et al.,Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma,Mol Ther,2016年,Vol. 24(2),pp. 354-363
橋本 直哉,脳腫瘍に対する免疫療法,京府医大誌 ,2017年,Vol. 126,pp. 405-415

Also Published As

Publication number Publication date
CA3093810A1 (en) 2019-09-19
KR102805003B1 (ko) 2025-05-13
US12152079B2 (en) 2024-11-26
AU2019234573B2 (en) 2026-01-22
AU2019234573A1 (en) 2020-10-08
JP2024026165A (ja) 2024-02-28
EP3765041A4 (en) 2021-12-22
IL277267A (en) 2020-10-29
IL314877B2 (en) 2026-05-01
MX2020009463A (es) 2021-03-09
EP3765041A1 (en) 2021-01-20
US20250043013A1 (en) 2025-02-06
JP2021518108A (ja) 2021-08-02
WO2019178078A1 (en) 2019-09-19
BR112020018670A2 (pt) 2021-01-05
IL277267B1 (en) 2024-09-01
IL314877A (en) 2024-10-01
IL277267B2 (en) 2025-01-01
US20210000875A1 (en) 2021-01-07
SG11202008795SA (en) 2020-10-29
KR20200131279A (ko) 2020-11-23
EA202091982A1 (ru) 2021-06-10
CN112236151A (zh) 2021-01-15
IL314877B1 (en) 2026-01-01
JP7745616B2 (ja) 2025-09-29

Similar Documents

Publication Publication Date Title
JP7745616B2 (ja) 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体
TWI787599B (zh) 嵌合抗原和t細胞受體及使用方法
US10189903B2 (en) Bispecific chimeric antigen receptors and methods of use thereof to treat cancer
JP7627080B2 (ja) B7h3キメラ抗原受容体を含む方法および組成物
US20220325241A1 (en) Immune effector cell for co-expressing chemokine receptor
JP7696958B2 (ja) ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法
WO2025221781A2 (en) Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
HK1205144B (en) Bispecific chimeric antigen receptors and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240213

R150 Certificate of patent or registration of utility model

Ref document number: 7438123

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150